CA2614526A1 - Formulation de benzimidazole - Google Patents

Formulation de benzimidazole Download PDF

Info

Publication number
CA2614526A1
CA2614526A1 CA002614526A CA2614526A CA2614526A1 CA 2614526 A1 CA2614526 A1 CA 2614526A1 CA 002614526 A CA002614526 A CA 002614526A CA 2614526 A CA2614526 A CA 2614526A CA 2614526 A1 CA2614526 A1 CA 2614526A1
Authority
CA
Canada
Prior art keywords
alkaline substance
dry
benzimidazole
alkaline
formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002614526A
Other languages
English (en)
Inventor
Poul Bertelsen
Peder Mohr Olsen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharma AS
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2614526A1 publication Critical patent/CA2614526A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CA002614526A 2005-07-11 2006-07-11 Formulation de benzimidazole Abandoned CA2614526A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DKPA200501019 2005-07-11
DKPA200501019 2005-07-11
US72785505P 2005-10-19 2005-10-19
US60/727,855 2005-10-19
PCT/DK2006/000409 WO2006105798A2 (fr) 2005-07-11 2006-07-11 Formulation de benzimidazole

Publications (1)

Publication Number Publication Date
CA2614526A1 true CA2614526A1 (fr) 2006-10-12

Family

ID=37492042

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002614526A Abandoned CA2614526A1 (fr) 2005-07-11 2006-07-11 Formulation de benzimidazole

Country Status (5)

Country Link
EP (1) EP1901719A2 (fr)
AU (1) AU2006230974C1 (fr)
CA (1) CA2614526A1 (fr)
EA (1) EA015535B1 (fr)
WO (1) WO2006105798A2 (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5228359B2 (ja) * 2007-04-12 2013-07-03 ニプロ株式会社 主薬粒子及びその製造方法ならびに口腔内崩壊錠
TWI441658B (zh) 2008-03-11 2014-06-21 Takeda Pharmaceutical 口腔崩解固體製劑
DK2468281T3 (en) 2009-08-19 2016-03-21 Eisai R&D Man Co Ltd Quinolinderivatholdig pharmaceutical composition
TR201000948A1 (tr) * 2010-02-09 2011-08-22 Sanovel İlaç San.Ve Ti̇c.A.Ş. Aripiprazol formülasyonları.
JP6038128B2 (ja) 2011-06-03 2016-12-07 エーザイ・アール・アンド・ディー・マネジメント株式会社 レンバチニブ化合物に対する甲状腺癌対象及び腎臓癌対象の反応性を予測及び評価するためのバイオマーカー
CN103479593B (zh) * 2013-05-10 2014-10-08 青岛双鲸药业有限公司 一种奥美拉唑肠溶片的制备方法
CN103386133A (zh) * 2013-07-09 2013-11-13 重庆莱美药业股份有限公司 一种质子泵抑制剂的口腔速溶制剂及其制备方法
PT3524595T (pt) 2014-08-28 2022-09-19 Eisai R&D Man Co Ltd Derivado de quinolina altamente puro e método para produção do mesmo
AU2016224583B2 (en) 2015-02-25 2021-06-03 Eisai R&D Management Co., Ltd. Method for suppressing bitterness of quinoline derivative
KR102662228B1 (ko) 2015-03-04 2024-05-02 머크 샤프 앤드 돔 코포레이션 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
CN104825414B (zh) * 2015-05-07 2018-11-16 山东新时代药业有限公司 一种稳定的s-泮托拉唑钠肠溶片
BR112017027227B1 (pt) 2015-06-16 2023-12-12 Eisai R&D Management Co., Ltd Agente anti-câncer
JP6553726B2 (ja) 2015-08-20 2019-07-31 エーザイ・アール・アンド・ディー・マネジメント株式会社 腫瘍治療剤
JP6581320B2 (ja) 2017-02-08 2019-09-25 エーザイ・アール・アンド・ディー・マネジメント株式会社 腫瘍治療用医薬組成物
EP3624800A4 (fr) 2017-05-16 2021-02-17 Eisai R&D Management Co., Ltd. Traitement du carcinome hépatocellulaire
CN113318079B (zh) * 2021-05-13 2024-01-09 江西博莱大药厂有限公司 一种提高三氯苯达唑颗粒溶出度的方法及其溶出度检测方法
CN115645373B (zh) * 2022-12-24 2024-01-30 山东理工职业学院 一种奥美拉唑钠片的制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5433959A (en) * 1986-02-13 1995-07-18 Takeda Chemical Industries, Ltd. Stabilized pharmaceutical composition
KR20010012402A (ko) * 1997-05-09 2001-02-15 세이지 파마슈티칼스, 인크. 안정한 약제학적 경구 투여형
CA2298823C (fr) * 1998-04-20 2011-06-07 Eisai Co., Ltd. Composition stabilisee comprenant un compose de type benzimidazole
WO2002026210A2 (fr) * 2000-09-29 2002-04-04 Geneva Pharmaceuticals Inc. Formulation d'inhibiteur de la pompe à protons
AR036354A1 (es) * 2001-08-31 2004-09-01 Takeda Chemical Industries Ltd Preparacion solida
CA2517289A1 (fr) * 2003-02-28 2004-09-10 Ranbaxy Laboratories Limited Compositions pharmaceutiques stables de rabeprazole et leurs procedes de fabrication
WO2004112756A1 (fr) * 2003-06-26 2004-12-29 Isa Odidi Capsules contenant un inhibiteur de la pompe a protons comprenant des unites secondaires differemment structurees permettant une liberation retardee de l'ingredient actif
WO2005009410A2 (fr) * 2003-07-17 2005-02-03 Dr. Reddy's Laboratories, Inc. Compositions pharmaceutiques a revetement gonflant

Also Published As

Publication number Publication date
AU2006230974C1 (en) 2012-02-02
EA200800290A1 (ru) 2008-08-29
WO2006105798A3 (fr) 2006-12-07
AU2006230974A1 (en) 2006-10-12
EA015535B1 (ru) 2011-08-30
AU2006230974B2 (en) 2011-09-29
EP1901719A2 (fr) 2008-03-26
WO2006105798A2 (fr) 2006-10-12

Similar Documents

Publication Publication Date Title
JP6934932B2 (ja) アンドロゲン受容体アンタゴニストの固体医薬組成物
AU2006230974C1 (en) Benzimidazole formulation
JP2016164170A (ja) プロトンポンプ阻害剤を含む制御放出組成物
JP7482182B2 (ja) プロトンポンプ阻害剤を含む経口用固形製剤組成物、それを含む経口用固形製剤及びその製造方法
CN119112820A (zh) 来那度胺的口服用片剂组合物
WO2011140446A2 (fr) Formulations pharmaceutiques
JP7581052B2 (ja) レナリドミドの経口用コーティング錠剤組成物
MX2014007331A (es) Sistema de multiunidades de granulos de liberacion inmediata.
WO2012018056A1 (fr) Composition comprimée
Sun et al. A microcrystalline cellulose based drug-composite formulation strategy for developing low dose drug tablets
AU2018203007B2 (en) Ceritinib formulation
CN104997748A (zh) 一种治疗高血压急症的硝苯地平缓释片剂及其制备工艺
CA2905423A1 (fr) Comprimes de sovaprevir
US20070020334A1 (en) Benzimidazole formulation
US20100055177A1 (en) Modified release composition of levetiracetam and process for the preparation thereof
WO2021074808A1 (fr) Composition pharmaceutique comprenant du sacubitril et du valsartan et son procédé de préparation
KR101845665B1 (ko) 프로톤 펌프 저해제를 포함하는 경구용 고형제제 조성물, 이를 포함하는 경구용 고형제제 및 그 제조방법
EP1909761B1 (fr) Préparation pharmaceutique comprenant du pantoprazole granulaire
WO2008015530A2 (fr) Formulation orale solide stable d'un medicament acide labile
Agiba et al. Modulatory effect of polymer type and concentration on drug release from sustained release matrix tablets of ranolazine: A comparative release kinetic study
JP2024003789A (ja) 時限放出型顆粒およびその用途
JP2018030810A (ja) ゲフィチニブを有効成分とする医薬錠剤の製造方法
WO2025190465A1 (fr) Composition pharmaceutique stable contenant du sélexipag et son procédé de préparation
KR20180060174A (ko) 덱스란소프라졸을 포함하는 경구용 정제 조성물, 이를 포함하는 경구용 정제 및 그 제조방법
GB2334212A (en) Modified release matrix formulation for cefaclor and cephalexin

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead

Effective date: 20151217